Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
2.840
-0.120 (-4.05%)
Apr 23, 2025, 11:39 AM EDT - Market open

Company Description

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.

Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.

The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy.

Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.

Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Adverum Biotechnologies, Inc.
Adverum Biotechnologies logo
Country United States
Founded 2006
IPO Date Jul 31, 2014
Industry Biotechnology
Sector Healthcare
Employees 155
CEO Laurent Fischer

Contact Details

Address:
100 Cardinal Way
Redwood City, California 94063
United States
Phone 650 656 9323
Website adverum.com

Stock Details

Ticker Symbol ADVM
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501756
CUSIP Number 00773U108
ISIN Number US00773U1088
Employer ID 20-5258327
SIC Code 2836

Key Executives

Name Position
Dr. Laurent Fischer President, Chief Executive Officer and Director
Linda M. Rubinstein M.A. Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Kishor Peter Soparkar J.D. Chief Operating Officer
Dr. Setareh Seyedkazemi Pharm.D. Chief Development Officer
Dr. Rabia Gurses Ozden M.D. Chief Medical Officer
Dr. R. Andrew Ramelmeier Ph.D. Chief Technology Officer
Dr. Romuald Corbau Ph.D. Chief Scientific Officer
Aneta Ferguson General Counsel
Dena House Chief People Officer
Carla Fiankan Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Apr 18, 2025 PRE 14A Other preliminary proxy statements
Apr 15, 2025 8-K Current Report
Apr 15, 2025 10-K Annual Report
Mar 31, 2025 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 31, 2025 8-K Current Report
Feb 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 13, 2025 SCHEDULE 13G/A Filing
Dec 19, 2024 S-8 Securities to be offered to employees in employee benefit plans
Dec 17, 2024 SCHEDULE 13G Filing